Hepatitis b patients may be able to ditch daily pills, new trial hopes

NCT ID NCT04782375

Completed Disease control Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 4 times

Summary

This study tests whether adults with chronic hepatitis B who have no liver scarring can safely stop taking antiviral drugs. The 140 participants have undetectable virus levels and negative HBeAg status. Researchers will monitor for viral relapse and liver problems over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: discontinuation of antiviral treatment
What this could lead to: If successful, this could show that some patients with chronic hepatitis B can safely stop long-term antiviral therapy without the virus coming back.
What could go wrong: This is a small, early-phase trial without a control group, so results may not apply widely. There is a risk of viral relapse or liver problems after stopping medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B CHRONIC

Contacts and locations

Locations

Asan Medical Center

Seoul, South Korea
Korea University Guro Hospital

Seoul, South Korea
Kyung-Hee University Hospital

Seoul, South Korea
Ulsan University Hospital

Ulsan, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.